TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. “We are excited to share data highlighting NS002’s potential for supe ...

Core Insights - NuGen Medical Devices Inc. is developing a next-generation needle-free injection system aimed at improving drug delivery technology, protected under international patent WO2021206553 [1][2] - The new system integrates a sterile internal insulin cartridge into the needle-free autoinjector, eliminating the need for external connectors and reducing dosing errors and contamination risks [2][6] - The innovation is expected to enhance patient experience for those requiring daily injections, positioning it as a competitor to pen-based injectors [3] Technical Highlights - The internal cartridge integration streamlines the injection process by removing the need for external adaptors and manual filling [6] - A backflow control mechanism is included to ensure precise and safe insulin delivery, addressing unique challenges of jet injection [6] - Improved usability is a focus, simplifying operation for patients and caregivers, which is anticipated to reduce training time and improve compliance [6] Future Milestones - NuGen plans to begin clinical investigations using its currently approved needle-free platform, allowing for parallel development of the new cartridge-based system [6] - The company aims to produce working prototypes within six months to showcase the technology and conduct usability studies [6] - Full tooling investment for scaled manufacturing and commercialization is expected to commence in early 2026 [6] Company Overview - NuGen Medical Devices specializes in next-generation needle-free devices for subcutaneous drug delivery, with its flagship InsuJet™ system approved in 42 countries [5]